Articles tagged with Tumor Growth
Activation of estrogen receptor β (ERβ) has been shown to limit tumor cell growth in breast cancer. In mouse models, cancer cells with activated ERβ did not grow well. Conversely, breast cancer patients with activated ERβ in their tissue had increased disease-free survival rates.
Researchers at Rochester Institute of Technology create algorithms to quantify lung nodule growth on CT scans, identifying small cancers and obviating risky biopsies. The software compensates for background factors and estimates nodule volumes, enabling accurate doubling time calculation and malignant growth detection.
Researchers at JAX Laboratory have identified a protein involved in both wound healing and tumor growth as a potential therapeutic target. The study found that manipulating this protein could stimulate healing in wound patients while dialing back cancerous proliferation.
Researchers identified a protein called CFIm25, which regulates messenger RNA length and promotes tumor growth. Restoring CFIm25 levels in brain tumors dramatically reduced their growth, providing a potential novel therapeutic strategy.
Researchers from the University of Notre Dame have uncovered a novel mechanism by which carcinoma-associated fibroblasts (CAFs) contribute to tumor progression. CAFs block cell death through insulin-like growth factor-binding proteins, highlighting potential therapeutic targets for slowing breast cancer metastasis. Further pre-clinical...
Researchers discovered microRNA-10a regulates human airway smooth muscle cell growth and inhibits PI3 kinase, a master regulator of cell proliferation. This finding offers a new approach to treating both asthma-induced muscle thickening and cancerous tumor growth.
Researchers found that triclosan and octylphenol promote breast cancer cell growth and tumor development in lab tests. The study's findings suggest that exposure to these endocrine-disrupting chemicals may significantly increase the risk of breast cancer development.
Researchers at Uppsala University discovered a new type of cell communication that suppresses blood vessel formation and delays tumour growth. Fluctuating levels of the molecule NRP1 can inhibit VEGF signals, leading to delayed tumour growth and potentially complete inhibition if trans communication occurs early in tumour development.
Researchers found that hypoxia stimulates the mislocation of SPOP to the cytoplasm, promoting rapid tumor growth. This shift enables SPOP to degrade key tumor-suppressor proteins, such as PTEN, leading to cancer progression. Understanding this mechanism may lead to new therapeutic approaches.
Researchers at UT Arlington found that exposure to BPA can increase HOTAIR expression in breast tissue and tumor cells, potentially contributing to breast cancer growth. The study's results suggest a link between BPA and tumor genesis in addition to tumor growth.
A new study published in Cancer Research found that fragmented sleep accelerates cancer growth by altering the immune system's response to tumors. Well-rested mice had primarily M1-type tumor-associated macrophages, while sleep-fragmented mice had primarily M2-type macrophages that promoted tumor growth.
Researchers found a significant inverse association between aspirin use and vestibular schwannoma growth in a retrospective series of 689 people. Aspirin intake may inhibit tumor growth, providing a potential therapeutic role for this anti-inflammatory medication.
Researchers found that metformin inhibits mTOR pathway, which supports cancer growth, rather than activating AMPK. Metformin may still be useful for cancer treatment, but clinicians should use caution when interpreting data.
Scientists at the University of Copenhagen have identified a specific sugar molecule that aids in the growth of cancer cells. The discovery, published in PNAS, could lead to new ways to diagnose and treat cancer.
Scripps Florida scientists discover that angiomotin is required for Yap-mediated tumor growth, challenging earlier findings of its inhibitory role. The study sheds light on a previously unknown pathway regulating cancer progression.
Researchers found that ERBB3 expression was enhanced in luminal breast cancers compared to other subtypes. The addition of an ERBB3 antibody promoted cancer cell death and decreased tumor growth in vitro.
Researchers at Johns Hopkins Bloomberg School of Public Health found that NRF2 signaling plays a role in regulating cell metabolism, leading to increased energy production and tumor cell proliferation. The study demonstrates the importance of targeting Nrf2 with small molecule inhibitors to intervene in therapeutic resistance.
Research published in BioMed Central's Stem Cell Research & Therapy found that injecting human stem cells into mice with tumors slowed down tumor growth. The study suggests that stem cells may restrict oxygen and nutrient delivery to the tumor, limiting cell division.
A novel monoclonal antibody targeting SFRP2 has been shown to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma. The antibody is the first therapeutic discovered that targets SFRP2, a protein linked to angiogenesis and cancer progression.
The novel inhibitor XL-184 (Cabozantinib) showed significant tumor growth decrease in 12 colorectal cancer explants, with 8 exhibiting stable disease. The drug targets both VEGFR2 signaling pathway and c-MET for survival of tumor cells.
A team of UC Davis scientists found that epoxy docosapentaenoic acid (EDP) inhibits angiogenesis, cutting off oxygen and nutrients that fuel tumor growth. EDP reduces the growth and spread of tumors in mice by starving them of necessary blood vessels.
Researchers found that blocking substance P binding to its receptor NK1 with the anti-nausea drug Emend halted brain tumor growth and caused cell death in tumor cells. This breakthrough offers new opportunities for studying possible brain tumor treatments.
A recent UEF study reveals that high cell sugar concentrations boost hyaluronan production, which can fuel cancer growth. Regulating hyaluronan levels may hold the key to preventing cancer progression.
Researchers discovered that interfering with Hexokinase-2 reduces medulloblastoma's aggressiveness and allows long-term survival in mice. The enzyme plays a key role in aerobic glycolysis, a process also used by rapidly dividing cells, including cancer cells.
Researchers at Yale School of Medicine have identified a key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis. The study reveals a connection between Lin28 and BMP4, which has implications for developing novel targeted therapies.
Researchers at McGill University have discovered AMPK's role in restricting cancer cell growth by regulating metabolism and preventing the use of sugar to fuel growth. AMPK, a tumour suppressor, can help control tumour development by targeting energy levels and promoting healthy cellular function.
A new study reveals that the SIRT6 gene plays a critical role in suppressing cancer growth by repressing aerobic glycolysis and inhibiting Myc activity. The loss of SIRT6 protein in mice increases tumor size and aggressiveness, highlighting its potential as a tumor suppressor.
A study by Georgetown University Medical Center researchers found that high glucose diets increase mutant p53 gene expression in mice, which drives tumor growth. Reducing glucose intake through starvation or low-carb diet slows down cancer growth.
Researchers at UCLA's Broad Center of Regenerative Medicine have discovered that the Trop2 protein promotes the self-renewal of cancer cells through a mechanism involving cleavage. This finding may lead to the development of new therapies that block Trop2 molecular signaling, stopping tumor growth in various epithelial malignancies.
Research reveals that Col6 protein's endotrophin alter tumor environment promoting growth and metastasis in mice. Reduced endotrophin expression linked to lower tumor burden and fewer metastases.
Researchers found that blocking galectin-1 in mice with established Kaposi sarcomas slowed tumor growth by suppressing blood vessel formation. This breakthrough holds promise for new treatment options for patients with KS and may also be effective for other diseases characterized by aberrant blood vessel growth.
Research at Thomas Jefferson University discovered that senescent cells in the tumor microenvironment produce nutrients for cancer cells via autophagy, supporting their growth. This finding suggests that aging is a key factor in driving tumor growth and metastasis.
Researchers have identified a molecule, PDE4, that plays a key role in regulating the division of tumor cells and blood vessel growth in lung cancer. By blocking PDE4, they were able to significantly reduce tumor growth in laboratory experiments and mouse models.
A new study published in Radiology journal reveals that lung cancers diagnosed through annual rounds of computed tomography (CT) screening exhibit similar growth rates and cell-type distributions compared to those found in clinical practice. The findings suggest a less aggressive approach for diagnosis and treatment of sub-solid lesions.
Princeton University researchers created a cellular automation model to investigate complex tumor-host interactions in cancer, revealing diverse growth dynamics and morphologies under varying pressures.
Scientists have combined NO- and H2S-releasing designer aspirins into a hybrid substance called NOSH-aspirin, which appears more effective in controlling cancer growth than either of its predecessors. The new compound inhibits the growth of various cancer cells, including breast, colon, and leukemia, with minimal harm to normal cells.
A new study reveals how tumours exploit the lymphatic system to evade immune cells, but also identifies a weakness that can be targeted to boost vaccine efficacy. By understanding this mechanism, future cancer vaccines may be able to bypass the tumour's defence and effectively kill cancer cells.
Researchers at Boston University have created a 3D model that simulates the growth of cancer tumors, suggesting that softening of cancer cells accelerates proliferation and extends lifetime, leading to rapid tumor growth. The study provides a new quantitative approach to understanding tumor development based on mechanical properties.
DIM inhibits ovarian cancer cell growth by blocking STAT3 activation and reducing IL-6 levels. The combination of DIM and cisplatin suppresses tumor growth in mice by an extra 50% compared to cisplatin alone.
Researchers precisely measured protein levels in 1,400 tumor biopsies and found no correlation between HER3 protein levels and Herceptin treatment outcome. The study suggests that single biomarkers like HER3 are not predictive of benefit from Herceptin treatment.
Researchers at VTT Technical Research Centre of Finland discovered a single cell protein that inhibits both cell migration and growth in aggressive breast cancer cells. This finding suggests an interconnected regulation of uncontrollable growth and metastasis, potentially leading to new medicine development.
A study published in Journal of Interferon & Cytokine Research found that Tyk2 protein helps suppress breast tumor growth and metastasis. Mice with normal Tyk2 expression were less susceptible to breast cancer, suggesting boosting Tyk2 activity may be beneficial for treating the disease.
Researchers at Karolinska Institutet have found that treating common Cytomegalovirus (CMV) can reduce tumour growth and size. CMV is found in 70-75% of adults and plays a central role in brain tumours, breast cancer, colon cancer, and prostate cancer.
Scientists from the University of Miami and Germany have created a model to predict cancer tumor growth and progression, which could lead to highly individualized treatment strategies. The model analyzes images of tumor sections and predicts the most likely course of the disease.
A study by Andrew Weng and colleagues identifies insulin growth factor-1 (IGF-1) as a key driver of cancer growth in T cell acute lymphoblastic leukemia. Blocking the IGF-1 receptor improves survival rates in mice, suggesting a potential new treatment strategy.
Scientists at Dana-Farber Cancer Institute have identified a novel subtype of breast cancer that grows in response to androgen but not estrogen. The study reveals the signaling pathways involved in its growth and demonstrates that drugs capable of blocking these pathways can inhibit tumor growth.
A team of researchers has identified a new breast cancer tumor suppressor called Runx3, which regulates gene expression and targets the estrogen receptor alpha. The study found that Runx3 suppressed breast cancer cell growth and inhibited tumor formation in mice, offering potential benefits for early detection and treatment.
A new study has identified PI3Kinase gamma as a crucial protein in tumor growth and inflammation. Disrupting this enzyme prevents tumor cells from attracting immune cells, slowing down tumor development and metastasis.
A UNC laboratory study shows that Tacrolimus, a commonly used organ transplant rejection medication, inhibits breast cancer growth by over 70 percent in pre-clinical studies. The drug works by blocking new blood vessel growth to tumors, a therapeutic strategy to inhibit tumor growth.
A new study links obstructive sleep apnea (OSA) to increased tumor growth and aggressiveness in melanoma cancer cells in mice. Recurrent hypoxia, a hallmark of OSA, enhances tumor proliferation and necrosis.
A team of researchers from the University of Montreal has made a breakthrough in understanding the genetics of Meier-Gorlin Syndrome, a rare disorder characterized by short stature and abnormal development. The study identified three genes - ORC1L, ORC4L, and CDT1 - that play a critical role in DNA replication and cell growth.
A Tel Aviv University researcher has found that fibroblasts, a type of connective tissue cell, can be coerced into supporting inflammation and tumor growth. This discovery opens new avenues for drug research and may help manage inflammation to reduce cancer growth.
A new study shows that protein HRG activates specific immune cells to inhibit tumor growth and metastasis. HRG enhances chemotherapy effects and transforms inflammatory cells from promoting to inhibiting tumor growth.
Two compounds, called PITs (non-phosphoinositide PIP3 inhibitors), show promise in halting cancer growth by inducing cell death and limiting tumor growth in mice. These compounds interfere with cell signaling pathways, positioning them as a promising new approach to cancer treatment.
Individual cancer-causing mutations have a minor effect on tumor growth, increasing cell division rates and contributing to the accumulation of multiple mutations. The research suggests that significant tumor growth requires the slow accumulation of multiple mutations over years, explaining why many cancer-driving mutations are needed.
Researchers found that TAL1 promotes the expression of NKX3.1 in T cell acute lymphoblastic leukemia cells, driving their growth and proliferation. Eliminating NKX3.1 halted the growth of these cancerous cells in culture and after injection into mice.
The Society for Industrial and Applied Mathematics (SIAM) awards the Julian Cole Lectureship every four years to recognize outstanding contributions to mathematical characterization and solution of challenging problems. This year, Professor John King received the award for his work on mathematical modeling of tumor growth.
Researchers found that human breast cancer cells overexpress the alpha 9 subunit of the nAchR, promoting tumor growth. Reducing α9-nAchRs inhibited tumor growth in laboratory experiments.
Researchers found that chronic morphine use decreases levels of tumor angiogenesis, mediated by suppression of signaling induced by low oxygen concentrations. This effect suggests morphine may inhibit tumor growth and serve as an anti-angiogenic agent in cancer pain management.
A study found that mammographic tumor detectability decreases with age, primarily due to denser breast tissue masking tumors. The study suggests that lowered mammographic tumor detectability accounts for 79% of the poorer sensitivity in mammography screening among younger women.